ConductScience.org, home

Paper39724243

Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.

Koul V and 5 others. Arch Microbiol, 2024. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae. Papers, record 39724243. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39724243

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Breaking the resistance: integrative approaches with novel therapeutics against Klebsiella pneumoniae.
PubMed
Journal
Arch Microbiol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
3.72, provisional
iCite
Revised in PubMed
2025-01-24
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Koul VVimarishi
2Sharma AAkshi
3Kumari DDiksha
4Jamwal VVishwani
5Palmo TTashi
6Singh KKuljit

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Bacterial AgentsMajor topic
Drug Resistance, Multiple, BacterialMajor topic
Klebsiella InfectionsMajor topic
Klebsiella pneumoniaeMajor topic
Humans
Biological Products
Drug Discovery
Drug Repositioning

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
CSPS24/RDSF/IIIM/IHP24/03CSIR-R&D Seed Fund (RDSF)PubMed

Source PubMed

Download CSV of grants

References131

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132201008Antimicrobial resistance, mechanisms and its clinical significance.Dis Mon2020https://conductscience.org/library/papers/32201008PubMed
233134741An exegesis of bacteriophage therapy: An emerging player in the fight against anti-microbial resistance.AIMS Microbiol2020https://conductscience.org/library/papers/33134741PubMed
335163939Synthesis, Antimicrobial, Anti-Virulence and Anticancer Evaluation of New 5(4H)-Oxazolone-Based Sulfonamides.Molecules2022https://conductscience.org/library/papers/35163939PubMed
434276590Metabolite Profiling of Malaysian Gracilaria edulis Reveals Eplerenone as Novel Antibacterial Compound for Drug Repurposing Against MDR Bacteria.Front Microbiol2021https://conductscience.org/library/papers/34276590PubMed
534476772Current Stage in the Development of Klebsiella pneumoniae Vaccines.Infect Dis Ther2021https://conductscience.org/library/papers/34476772PubMed
633510482Natural products in drug discovery: advances and opportunities.Nat Rev Drug Discov2021https://conductscience.org/library/papers/33510482PubMed
735865823Isolation and Characterization of vB_kpnM_17-11, a Novel Phage Efficient Against Carbapenem-Resistant Klebsiella pneumoniae.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/35865823PubMed
830207815Multidrug-resistant Klebsiella pneumoniae: challenges for treatment, prevention and infection control.Expert Rev Anti Infect Ther2018https://conductscience.org/library/papers/30207815PubMed
930447360Facile green synthesis of silver nanoparticles using Berberis vulgaris leaf and root aqueous extract and its antibacterial activity.Int J Biol Macromol2019https://conductscience.org/library/papers/30447360PubMed
1030026034Cerium oxide nanoparticles as potential antibiotic adjuvant. Effects of CeO2 nanoparticles on bacterial outer membrane permeability.Biochim Biophys Acta Biomembr2018https://conductscience.org/library/papers/30026034PubMed
1130452654Klebsiella pneumoniae infection biology: living to counteract host defences.FEMS Microbiol Rev2019https://conductscience.org/library/papers/30452654PubMed
1236558132Applications of Essential Oils and Plant Extracts in Different Industries.Molecules2022https://conductscience.org/library/papers/36558132PubMed
1319035777Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.Clin Infect Dis2009https://conductscience.org/library/papers/19035777PubMed
1436978495Design and Synthesis of Novel Antimicrobial Agents.Antibiotics (Basel)2023https://conductscience.org/library/papers/36978495PubMed
1532152527Antibiotics in the clinical pipeline in October 2019.J Antibiot (Tokyo)2020https://conductscience.org/library/papers/32152527PubMed
1637113135Synergistic effect and antibiofilm activity of the antimicrobial peptide K11 with conventional antibiotics against multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae.Front Cell Infect Microbiol2023https://conductscience.org/library/papers/37113135PubMed
1737972089Synergistic effect of two antimicrobial peptides, BP203 and MAP-0403 J-2 with conventional antibiotics against colistin-resistant Escherichia coli and Klebsiella pneumoniae clinical isolates.PLoS One2023https://conductscience.org/library/papers/37972089PubMed
1838953095Exploration of Antimicrobial Peptides in the Treatment of Gentamicin-Resistant Klebsiella pneumoniae Infection.Infect Drug Resist2024https://conductscience.org/library/papers/38953095PubMed
1931114568Distinct Roles of Outer Membrane Porins in Antibiotic Resistance and Membrane Integrity in Escherichia coli.Front Microbiol2019https://conductscience.org/library/papers/31114568PubMed
2031847614Antibiotic combination therapy against resistant bacterial infections: synergy, rejuvenation and resistance reduction.Expert Rev Anti Infect Ther2020https://conductscience.org/library/papers/31847614PubMed

See all 131 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42676813Antibiotic resistance in K. pneumoniae: perspectives, challenges, health risks, therapeutic approaches.Front Microbiol2026https://conductscience.org/library/papers/42676813PubMed
42517888Characterization of beddomeilactone amide as bacterial DNA gyrase inhibitor: in vitro evaluation and computational insights.Med Chem Res2026https://conductscience.org/library/papers/42517888PubMed
42446684Discovery of new bioactive secondary metabolites from the stem bark of oroxylum indicum: isolation, structural identification, antimicrobial and cytotoxicity assessment.Med Chem Res2026https://conductscience.org/library/papers/42446684PubMed
42429828N-sulfonylated indole hydrazone hybrid targeting Staphylococcus aureus with compelling antibiofilm and membrane-disrupting properties.Naunyn Schmiedebergs Arch Pharmacol2026https://conductscience.org/library/papers/42429828PubMed
41849041Deciphering the potentiality of Andrographolide derivatives against Pseudomonas aeruginosa: in vitro analysis and mechanistic insights.World J Microbiol Biotechnol2026https://conductscience.org/library/papers/41849041PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39724243

GET https://conductscience.org/api/papers/v1/39724243/references?page=2